Lipid based drug delivery systems for oral, transdermal and parenteral delivery: Recent strategies for targeted delivery consistent with different clinical application

Srivastav, Anurag Kumar; Karpathak, Supriya; Kumar, Mandhir; Kumar, Deepak; Misra, Durga Prasanna; Agarwal, Vikas

doi:10.1016/j.jddst.2023.104526

Cited by 11 publications

(7 citation statements)

References 215 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, the materials obtained demonstrated cytotoxicity towards the tested cell lines. In turn, Jing et al [203] carried out studies on albuminbased nanocomposites incorporated with N5,N6-Bis(2-fluorophenyl) [1,2,5]oxadiazolo [3,4b]pyrazine-5,6-diamine (BAM15), an active substance that may prevent obesity and its potential symptoms. The experiments performed demonstrated the excellent biocompatibility of prepared carriers and their liver targeting capability, possibly due to the presence of albumin within their structure.…”

Section: Albumin-based Drug Carriersmentioning

confidence: 99%

“…In today's world, developing modern therapies and strategies for delivering active substances requires innovative approaches [1,2] that balance therapeutic effectiveness with minimizing adverse effects. Traditional drug delivery methods include classical approaches such as oral, intravenous, dermal, or muscular administration of the active substance without the use of special carriers [3,4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

Jamroży,

Kudłacik-Kramarczyk,

Drabczyk

et al. 2024

IJMS

View full text Add to dashboard Cite

Studies on bionanocomposite drug carriers are a key area in the field of active substance delivery, introducing innovative approaches to improve drug therapy. Such drug carriers play a crucial role in enhancing the bioavailability of active substances, affecting therapy efficiency and precision. The targeted delivery of drugs to the targeted sites of action and minimization of toxicity to the body is becoming possible through the use of these advanced carriers. Recent research has focused on bionanocomposite structures based on biopolymers, including lipids, polysaccharides, and proteins. This review paper is focused on the description of lipid-containing nanocomposite carriers (including liposomes, lipid emulsions, lipid nanoparticles, solid lipid nanoparticles, and nanostructured lipid carriers), polysaccharide-containing nanocomposite carriers (including alginate and cellulose), and protein-containing nanocomposite carriers (e.g., gelatin and albumin). It was demonstrated in many investigations that such carriers show the ability to load therapeutic substances efficiently and precisely control drug release. They also demonstrated desirable biocompatibility, which is a promising sign for their potential application in drug therapy. The development of bionanocomposite drug carriers indicates a novel approach to improving drug delivery processes, which has the potential to contribute to significant advances in the field of pharmacology, improving therapeutic efficacy while minimizing side effects.

show abstract

Section: Albumin-based Drug Carriersmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

Jamroży,

Kudłacik-Kramarczyk,

Drabczyk

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…83,84 Notably, curcumin-loaded nano micelles were recently developed for targeted delivery to the colon in ulcerative colitis treatment. 85,86…”

Section: Lipid Based Delivery System For Tddsmentioning

confidence: 99%

Revolutionizing transdermal drug delivery: unveiling the potential of cubosomes and ethosomes

Balakrishnan,

Gopi

2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…These systems used lipid-based particles to enhance drug delivery. Here are some classes of lipid particulate delivery systems within LBDDS [ 5 , 116 – 119 ]: Lipid Nanoparticles (LNPs) . Lipid nanoparticles are colloidal carriers with sizes typically in the nanometer range.…”

Section: Oral Bioavailability Enhancement Approachesmentioning

confidence: 99%

Lipid Horizons: Recent Advances and Future Prospects in LBDDS for Oral Administration of Antihypertensive Agents

Preeti,

Sambhakar,

Malik

et al. 2024

International Journal of Hypertension

View full text Add to dashboard Cite

The lipid-based drug delivery system (LBDDS) is a well-established technique that is anticipated to bring about comprehensive transformations in the pharmaceutical field, impacting the management and administration of drugs, as well as treatment and diagnosis. Various LBDDSs verified to be an efficacious mechanism for monitoring hypertension systems are SEDDS (self-nano emulsifying drug delivery), nanoemulsion, microemulsions, vesicular systems (transferosomes and liposomes), and solid lipid nanoparticles. LBDDSs overcome the shortcomings that are associated with antihypertensive agents because around fifty percent of the antihypertensive agents experience a few drawbacks including short half-life because of hepatic first-pass metabolism, poor aqueous solubility, low permeation rate, and undesirable side effects. This review emphasizes antihypertensive agents that were encapsulated into the lipid carrier to improve their poor oral bioavailability. Incorporating cutting-edge technologies such as nanotechnology and targeted drug delivery, LBDDS holds promise in addressing the multifactorial nature of hypertension. By fine-tuning drug release profiles and enhancing drug uptake at specific sites, LBDDS can potentially target renin-angiotensin-aldosterone system components, sympathetic nervous system pathways, and endothelial dysfunction, all of which play crucial roles in hypertension pathophysiology. The future of hypertension management using LBDDS is promising, with ongoing reviews focusing on precision medicine approaches, improved biocompatibility, and reduced toxicity. As we delve deeper into understanding the intricate mechanisms underlying hypertension, LBDDS offers a pathway to develop next-generation antihypertensive therapies that are safer, more effective, and tailored to individual patient needs.

show abstract

Lipid based drug delivery systems for oral, transdermal and parenteral delivery: Recent strategies for targeted delivery consistent with different clinical application

Cited by 11 publications

References 215 publications

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

Advanced Drug Carriers: A Review of Selected Protein, Polysaccharide, and Lipid Drug Delivery Platforms

Revolutionizing transdermal drug delivery: unveiling the potential of cubosomes and ethosomes

Lipid Horizons: Recent Advances and Future Prospects in LBDDS for Oral Administration of Antihypertensive Agents

Contact Info

Product

Resources

About